Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion
BO42533
Phase 2 small_molecule active
Quick answer
Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion for Squamous cell carcinoma of the head and neck (SCCHN) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Squamous cell carcinoma of the head and neck (SCCHN)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active